UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Craig Collard - Chief Executive Officer David Szekeres - Executive Vice President & Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Rohit Bhasin - Needham & Company Carl Byrnes - Northland Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q1 2023 Earnings Conference. Before we begin, I would like t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 94-2875566 (State or other jurisdicti ...

Heron Pipeline of 4 Approved Products With $107.7 million in | --- | --- | --- | --- | |------------|------------------------------------------------------------------|------------------------------------|----------------------------------------------------------------| | | ZYNRELEF® (bupivacaine and meloxicam) extended-release solution | sNDA#2 PDUFA Goal October 23, 2023 | US FDA Approved for postsurgical analgesia for up to 72 hours* | | Acute Care | APONVIE™ (aprepitant) injectable emulsion | Launched M ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chairman and Chief Executive Officer John Poyhonen – President and Chief Commercial Officer Conference Call Participants Josh Schimmer – Evercore Brandon Folkes – Cantor Fitzgerald Serge Belanger – Needham and Company Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Heron Thera ...

Forward-Looking Statements Heron Pipeline of 4 Approved Products With $106.7 million in | --- | --- | --- | --- | --- | --- | |---------------|-----------------------------------|-------------|----------|--------------------------------------|----------| | | | PRECLINICAL | CLINICAL | NDA | APPROVED | | | | | | | | | | SUSTOL® (granisetron) | | | US FDA Approved for CINV Prevention* | | | Oncology Care | extended-release injection | | | | | | | CINVANTI® | | | | | | | (aprepitant) injectable emulsion | | | ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - CEO and Chairman John Poyhonen - President and Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Josh Schimmer - Evercore Serge Belanger - Needham and Company Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2022 Earnings Conference. As a reminder, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other juris ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chief Executive Officer and Chairman John Poyhonen – President and Chief Commercial Officer Conference Call Participants Josh Schimmer – Evercore Serge Belanger – Needham and Company Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q2 2022 Earnings Confer ...